Neuronetics announced a new peer-reviewed publication in the Journal of Clinical Psychiatry, presenting real-world evidence of the efficacy of NeuroStar Advanced Therapy for adult patients who suffer concurrently from anxiety symptoms and major depressive disorder , also known as anxious depression…In my years of psychiatric practice, I have seen many depressed patients experiencing significant anxiety symptoms that can be debilitating," said Dr. Todd Hutton, M.D., Chief Medical Director at Southern California TMS Center. "These results are impressive because they further illustrate the mental health benefits that NeuroStar TMS can provide for many patients with psychiatric disorders like anxious depression. Having access to this large registry allows us to further the research and establish best practices for treating physicians."Neuronetics received FDA clearance to treat anxious depression with NeuroStar Advanced Therapy in July 2022.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on STIM:
- Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
- Neuronetics settles litigation against Brainsway
- Brainsway resolves Neuronetics litigation
- Neuronetics Settles Litigation Against BrainsWay
- Neuronetics momentum likely to prove durable, says Piper Sandler